Lundbeck’s VYEPTI intravenous migraine treatment becomes first to gain FDA approval
In clinical trials, the new IV treatment was shown to reduce symptoms of migraines — including headaches, nausea…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
24 Feb 20
In clinical trials, the new IV treatment was shown to reduce symptoms of migraines — including headaches, nausea…
24 Feb 20
Trulicity is indicated for major adverse cardiovascular events (MACE) in type 2 diabetes patients, with cardiovascular (CV) disease…
24 Feb 20
The Phase 3 ATTRACTION-3 clinical trial, which evaluated Opdivo compared to chemotherapy, has supported the Japanese regulatory approval
21 Feb 20
The deal expands Lilly’s portfolio of medicines with the addition of lebrikizumabfor, for atopic dermatitis and QBREXZA for…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
The CytoSorb works by removing toxins from the blood in order to reduce inflammation - and avoiding the…
20 Feb 20
The combination of PADCEV and KEYTRUDA is indicated as treatment for unresectable metastatic urothelial cancer in patients
20 Feb 20
Tecentriq is an initial monotherapy for patients with advanced non-squamous and squamous non-small cell lung cancer (NSCLC)
19 Feb 20
About 70% of the antibiotics used globally are administered to farm animals, such as cattle, swine and poultry
19 Feb 20
WuXi Vaccines is a joint venture vaccine Contract Development and Manufacturing Organization (CDMO) between WuXi Biologics and Shanghai…
19 Feb 20
VYNDAQEL is the only EC-approved medicine to reduce mortality and frequency of cardiovascular-related hospitalizations in adults with hereditary…